The Theranostic Value of STARD3 in Colorectal Cancer: The STAR Study
Recruiting · NCT06136949 · Observational (researchers observe without assigning treatment) · Lead sponsor: Centro di Riferimento Oncologico - Aviano
View the official record on ClinicalTrials.gov →What this trial is about
This study aims at verifying the overexpression of STARD3 in both early and advanced CRC patients derived tissues, to identify the pathways underpinning tumorigenesis and cancer progression in which STARD3 is involved. Moreover its role as a dynamic biomarker of treatment response and its part in treatment sensitivity will be explored.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Histologically confirmed diagnosis of colorectal cancer, independently from diagnosis stage.
- Age ≥18 years.
- Signed informed consent form.
- Availability of tissue and blood samples stored at the Institutional Biobank for research purposes.
Exclusion criteria
- Patients for which the tumour biobanking process could compromise the diagnostic assessments.
- Pregnancy or breast-feeding.
- History of concomitant or previous malignancy in the previous 5 years, except for adequately treated cutaneous squamous cell carcinoma or surgically removed in situ cervical carcinoma.
Where it is running
1 location listed.
- Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS - Aviano, Pordenone, Italy